ArticleHIV medicine2025
Weight gain on tenofovir alafenamide fumarate-based therapy compared to tenofovir disoproxil fumarate- and abacavir-based therapy in children and young people living with HIV in Europe.
Article in HIV medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Changes in Body Mass Index in Children and Adolescents Living With Human Immunodeficiency Virus in Europe and Thailand Starting Dolutegravir.Open forum infectious diseases · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
objectiveTo compare BMI-for-age z-score (zBMI) changes in treatment-experienced children and young people living with HIV aged 6 to <25 years on tenofovir alafenamide fumarate (TAF) to those on tenofovir disoproxil fumarate (TDF) and abacavir (ABC).
methodsCohort study of children and young people living with HIV from 12 European countries were grouped by drug exposure: 1 - on TAF with prior TDF use; 2 - on TAF no prior TDF; 3 - on TDF; and 4 - on ABC. Outcomes, adjusted for characteristics at drug start, were (i) incidence of overweight or obesity by 96 weeks, (ii) zBMI change 48 weeks before/after drug start, (iii) association between TAF/TDF/ABC and anchor drug on zBMI change and (iv) factors associated with zBMI change on TAF over 96 weeks.
resultsOverall, 162, 189, 270 and 144 were in groups 1, 2, 3 and 4, respectively. Median ages at drug start were 16, 13, 14 and 12 years. Obesity incidence by 96 weeks was 16%, 13%, 6% and 12% and higher on TAF than TDF (p = 0.018) but comparable to ABC (p = 0.568). Similar trends were seen for overweight/obesity, although differences were not significant. Over 48 weeks, zBMI increased at a higher rate on TAF than TDF (p = 0.001) but similar to ABC (p = 0.652). zBMI change was higher after than before drug start in group 1 (p = 0.059) but similar in other groups. Over 96 weeks zBMI change on TAF/TDF/ABC combined with dolutegravir vs. other anchor drugs was not statistically different (p = 0.196). zBMI change on TAF varied by age (p = 0.001), prior TDF (p = 0.019), viral load (p = 0.042) and zBMI (p = 0.004) at TAF start.
conclusionzBMI increased on TAF, faster than TDF, but similar to ABC. Weight gain on TAF was associated with multiple factors including prior TDF use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.